Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
Top Cited Papers
- 1 July 2015
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 51 (11), 1405-1414
- https://doi.org/10.1016/j.ejca.2015.03.015
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerNew England Journal of Medicine, 2013
- PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal CancerClinical Colorectal Cancer, 2012
- Mortality by Stage for Right- Versus Left-Sided Colon Cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare DataJournal of Clinical Oncology, 2011
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Outcome of right- and left-sided colonic and rectal cancer following surgical resectionColorectal Disease, 2010
- Colon cancer in Iceland—A nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients ageInternational Journal of Cancer, 2010
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers?Annals of Surgical Oncology, 2008
- Are there two sides to colorectal cancer?International Journal of Cancer, 2002
- C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomasEuropean Journal Of Cancer, 1996